[
  {
    "ts": null,
    "headline": "AbbVie in talks to acquire Gilgamesh Pharmaceuticals, Bloomberg News reports",
    "summary": "Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, citing people familiar with the matter. The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis treatment, Humira, lost patent protection. Gilgamesh is a clinical-stage company developing therapies for psychiatric disorders, including depression, anxiety and post-traumatic stress disorder.",
    "url": "https://finnhub.io/api/news?id=138d251f58db0b8fb5df5c6ccdb50ac5722a07869482e60596d181565df17088",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753914496,
      "headline": "AbbVie in talks to acquire Gilgamesh Pharmaceuticals, Bloomberg News reports",
      "id": 136148873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, citing people familiar with the matter. The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis treatment, Humira, lost patent protection. Gilgamesh is a clinical-stage company developing therapies for psychiatric disorders, including depression, anxiety and post-traumatic stress disorder.",
      "url": "https://finnhub.io/api/news?id=138d251f58db0b8fb5df5c6ccdb50ac5722a07869482e60596d181565df17088"
    }
  },
  {
    "ts": null,
    "headline": "Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect",
    "summary": "ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.",
    "url": "https://finnhub.io/api/news?id=388471b9fc1b335b8964c97c96478f44f8ed157ddef7f09bf4ddeed96e977b37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753884660,
      "headline": "Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect",
      "id": 136148858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.",
      "url": "https://finnhub.io/api/news?id=388471b9fc1b335b8964c97c96478f44f8ed157ddef7f09bf4ddeed96e977b37"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata",
    "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 83.8 (approximately 16% scalp hair coverage).1",
    "url": "https://finnhub.io/api/news?id=723f2cb04c1ea560774e898d8b55cd9329fc5ea4c6b2cd58a4efe308fc5d1572",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753878660,
      "headline": "AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata",
      "id": 136129749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 83.8 (approximately 16% scalp hair coverage).1",
      "url": "https://finnhub.io/api/news?id=723f2cb04c1ea560774e898d8b55cd9329fc5ea4c6b2cd58a4efe308fc5d1572"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
    "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
    "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753868462,
      "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
      "id": 136129640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
      "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Rinvoq Hits Main Endpoints in Alopecia Areata",
    "summary": "AbbVie's Rinvoq Hits Main Endpoints in Alopecia Areata",
    "url": "https://finnhub.io/api/news?id=9ba777cfac3403d9e244022cfe767b2eaf373d381f08ef62201d090ff19c1179",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753868100,
      "headline": "AbbVie's Rinvoq Hits Main Endpoints in Alopecia Areata",
      "id": 136167914,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie's Rinvoq Hits Main Endpoints in Alopecia Areata",
      "url": "https://finnhub.io/api/news?id=9ba777cfac3403d9e244022cfe767b2eaf373d381f08ef62201d090ff19c1179"
    }
  },
  {
    "ts": null,
    "headline": "Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever",
    "summary": "Being a great investor doesn't have to be complicated or expensive.",
    "url": "https://finnhub.io/api/news?id=70b0e10fd00d499fa09f71b057be806d665414399ba85929f8c9975b588dc6d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753863600,
      "headline": "Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever",
      "id": 136129751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Being a great investor doesn't have to be complicated or expensive.",
      "url": "https://finnhub.io/api/news?id=70b0e10fd00d499fa09f71b057be806d665414399ba85929f8c9975b588dc6d6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Thursday before market open. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=a8a131908deef6c8e9166aa70de8d2e622ce30f7943fd7b3bebcaae7e6a985ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753845271,
      "headline": "AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings",
      "id": 136129752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Thursday before market open. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=a8a131908deef6c8e9166aa70de8d2e622ce30f7943fd7b3bebcaae7e6a985ab"
    }
  }
]